Search

everythinglearnresearchcommunity

for

Search:↓

A single injection of PTH–CBD can increase bone density for up to a year.

Strontium zinc silicate may help treat osteoporosis and muscle loss.

Early phosphorus-calcium disorders in children with chronic kidney disease can lead to bone issues, highlighting the need for early bone density testing.

Strontium ranelate is no longer available for treatment.

Stopping Viviscal, a hair loss product, normalized the woman's elevated alkaline phosphatase levels.

PHAs are promising biodegradable materials for medical and dental uses.

Phosphodiesterase inhibitors like tadalafil can reduce cell growth in BPH caused by CD8+ T cells in low androgen conditions.

Weekly bicalutamide is safe and effective, with 50 mg/week recommended.

Proteasome inhibitors are promising treatments for various cancers, autoimmune diseases, and other conditions.

Wedelolactone may help prevent bone damage in breast cancer by blocking certain cell signals.

Understanding and managing side effects of hedgehog pathway inhibitors can improve treatment for advanced basal cell carcinoma.

Joint replacement surgery normalized high alkaline phosphatase levels in a patient with severe osteoarthritis.

Persistent hyperparathyroidism doesn't stop rickets healing or phosphate level normalization in VDDR2A.

Wedelolactone may help reduce bone loss with fewer side effects.

Bicalutamide may improve hair growth in postmenopausal women with mild side effects.

Bicalutamide may be a promising alternative treatment for female pattern hair loss.

Bicalutamide effectively treats prostate cancer but needs careful monitoring for side effects.

Hedgehog pathway inhibitors for advanced basal cell carcinoma can cause side effects, but managing them helps maintain treatment.

The drug IPI-926 is safe at 160 mg daily and may help treat certain tumors, especially basal cell carcinoma.

Phosphates strongly attach to cerium dioxide nanoparticles, showing specific spectral patterns.

New drugs face challenges due to limited evidence, and safety updates are advised for some existing medications.

Polycaprolactone and barium titanate composites show promise for use in biomedical applications.

Alpha-blockers and 5-alpha reductase inhibitors are main treatments for BPH, with new support for phosphodiesterase-5 inhibitors and beta-3 agonists.

Bone mineral and minocycline boost bone cell growth, aiding healing.

PTHrP is important for bone formation and may be targeted for osteoporosis treatment and longevity therapies.

The zinc-doped nanocomposite helps heal bone tissue effectively.

Finasteride weakens the bone-protective effects of certain blockers in low androgen conditions.